Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 163 pages

Showing 151 - 163


skin cancer

Dermoscopy Shows Characteristics of Cutaneous Metastases of Visceral Cancers

In a case series reported in JAMA Dermatology, Chernoff et al found that dermoscopic identification of vascular structures in cutaneous nodules in patients with known cancer diagnosis should raise suspicion for cutaneous metastasis. Study Details In the study, high-quality dermoscopic images of...

skin cancer
leukemia

Advanced Rai Stage Predicts Poor Outcome of Skin Cancer in CLL

Chronic lymphocytic leukemia (CLL) is associated with increased risk of skin cancer. In a study reported in JAMA Dermatology, Velez et al attempted to determine whether progression of CLL indicated by advanced Rai stage is associated with worse skin cancer outcomes. They found that risk of death...

skin cancer

Phase II Pilot Study Does Not Support Phase III Investigation of IV High-Dose Interferon Without Maintenance in Resected Melanoma

There is evidence that high-dose interferon alfa-2b consisting of 4 weeks of daily intravenous interferon alfa-2b followed by 48 weeks of subcutaneous maintenance interferon alfa-2b three times per week reduces risk of recurrence of resected melanoma and that response may depend on the early...

skin cancer

Imiquimod 5% Cream Inferior to Surgical Excision in Nodular and Superficial Basal Cell Carcinoma

In a noninferiority trial (SINS) reported in The Lancet Oncology, Bath-Hextall et al compared imiquimod 5% cream vs surgical excision for nodular and superficial basal cell carcinomas. Imiquimod cream was found to be inferior to surgical excision, but it may have a role in treatment of low-risk...

skin cancer

Study Explores Risk of New Primary Melanomas After Diagnosis of Stage III/IV Melanoma in Patients Not Receiving BRAF Inhibitors

In a study reported in the Journal of Clinical Oncology, Zimmer et al assessed the incidence of spontaneous new primary melanomas in patients with stage III or IV melanoma in order to help clarify risk of BRAF inhibitor–related new melanomas. They found that patients not receiving BRAF...

skin cancer

Predictors of Sentinel Lymph Node Metastasis Identified in Thin Melanomas

In a study reported in the Journal of Clinical Oncology, Dale Han, MD, of Moffitt Cancer Center, and colleagues in the Sentinel Lymph Node Working Group attempted to identify factors predictive of sentinel lymph node metastasis in thin melanomas. They found that Breslow thickness ≥ 0.75 mm, ...

skin cancer

Number and Distribution of Childhood Nevi Predict Melanoma in Subjects From Families With Familial Melanoma

In a study reported in JAMA Dermatology, Astrid Vredenborg, MD, of Leiden University Medical Center in the Netherlands, and colleagues evaluated whether acquired melanocytic nevi in childhood are an indicator of melanoma risk in children from families with familial melanoma. They found that number...

skin cancer
prostate cancer

Personal History of Prostate Cancer Increases Risk of Melanoma

History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer and recent data suggest that severe teenage acne is a risk factor for melanoma. In a study reported in the Journal of Clinical Oncology, Wen-Qing Li, PhD, of the...

skin cancer

Nivolumab Shows Activity in Ipilimumab-Refractory or -Naive Melanoma in Phase I Trial

In a phase I trial reported in the Journal of Clinical Oncology, Jeffrey S. Weber, MD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues assessed the effects of nivolumab—a human immunoglobulin G4-blocking antibody against the T-cell programmed death 1 checkpoint ...

skin cancer

Increases in Melanoma Incidence and Mortality Unremitting Over 6 Decades, Study Finds

In a study reported in Journal of Clinical Oncology, Alan C. Geller, MPH, RN, of the Harvard School of Public Health, and colleagues assessed long-term trends in the incidence and mortality of melanoma in Connecticut, a state with complete and consistent tumor registration. They found...

skin cancer

Dabrafenib Active in BRAF-600E/K Mutant Metastatic Melanoma

In a phase II study (BREAK-2) reported in Journal of Clinical Oncology, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori Fondazione G. Pascale, and colleagues assessed the activity of the mutated BRAF kinase inhibitor dabrafenib (Tafinlar) in patients with BRAF-V600E/K mutant metastatic...

skin cancer

Imatinib Active in Melanomas with KIT Mutation but Not KIT Amplification Alone

Mutations and amplifications in the KIT oncogene have been identified in mucosal and acral melanomas and in melanomas arising on chronically sun-damaged skin. In a multicenter phase II study reported in the Journal of Clinical Oncology, F. Stephen Hodi, MD, of Dana-Farber Cancer Institute, and...

skin cancer

In the Clinic: Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was...

Advertisement

Advertisement



Advertisement